Landscape of the complete RNA chemical modifications in the human 80S ribosome.
Taoka M, Nobe Y, Yamaki Y, Sato K, Ishikawa H, Izumikawa K, Yamauchi Y, Hirota K, Nakayama H, Takahashi N, Isobe T. · 2018
Read Landscape of the complete RNA chemical modifications in the human 80S ribosome. by Taoka M, Nobe Y, Yamaki Y, Sato K, Ishikawa H, Izumikawa K, Yamauchi Y, Hirota K, Nakayama H, Takahashi N, Isobe T. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6182160.txt.
Introduction
Taoka and co-authors present a research article in Nucleic Acids Research mapping every chemical modification in the human ribosome's RNA. As ribosomes are built, their RNAs gain chemical marks that keep protein production accurate. Faulty marking can distort the proteome, as seen in cancer and inherited disorders.
Using quantitative mass spectrometry, the team charted all modifications across the human 80S ribosome. They assigned 228 sites carrying 14 different kinds of modification. Most sit in the ribosome's working regions. All were typical of eukaryotic ribosomes, with no human-specific marks found, contrary to one recent report. The complete map is a reference for studying how these marks shape translation and disease.
Catalog record
| CREATOR | Taoka M, Nobe Y, Yamaki Y, Sato K, Ishikawa H, Izumikawa K, Yamauchi Y, Hirota K, Nakayama H, Takahashi N, Isobe T. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Landscape of the complete RNA chemical modifications in the human 80S ribosome By Masato Taoka, Yuko Nobe, Yuka Yamaki, Ko Sato, Hideaki Ishikawa, Keiichi Izumikawa, Yoshio Yamauchi, Kouji Hirota, Hiroshi Nakayama, Nobuhiro Takahashi, Toshiaki Isobe Published in: Nucleic Acids Research DOI: 10.1093/nar/gky811 ABSTRACT Abstract During ribosome biogenesis, ribosomal RNAs acquire various chemical modifications that ensure the fidelity of translation, and dysregulation of the modification processes can cause proteome changes as observed in cancer and inherited human disorders. Here, we report the complete chemical modifications of all RNAs of the human 80S ribosome as determined with quantitative mass spectrometry. We assigned 228 sites with 14 different post-transcriptional modifications, most of which are located in functional regions of the ribosome. All modifications detected are typical of eukaryotic ribosomal RNAs, and no human-specific modifications were observed, in contrast to a recently reported cryo-electron microscopy analysis. While human ribosomal RNAs appeared to have little polymorphism regarding the post-transcriptional modifications, we found that pseudouridylation at two specific sites in 28S ribosomal RNA are significantly reduced in ribosomes of patients with familial dyskeratosis congenita, a genetic disease caused by a point mutation in the pseudouridine synthase gene DKC1. The landscape of the entire epitranscriptomic ribosomal RNA modifications provides a firm basis for understanding ribosome function and dysfunction associated with human disease. INTRODUCTION Human ribosomes are comprised of two ribonucleoprotein subunits: the small subunit (40S) containing one ribosomal RNA (rRNA; 18S) and 33 ribosomal proteins, and the large subunit (60S) containing three rRNAs (5S, 5.8S, 28S) and 47 ribosomal proteins (1). In each subunit, rRNAs form the catalytic core for translation, and ribosomal proteins appear to stabilize and fine-tune ribosomal structure and function (2,3). Human ribosomes harbor numerous post-transcriptional modifications (PTMs), such as methylation or acetylation of the nucleotide base or the 2′-hydroxyl group of the ribose moiety, or conversion of uridine to pseudouridine (Ψ) (4–6). These PTMs are fundamental to global ribosome topology and functions (decoding, peptidyl transfer, translocation) and stabilize the structure either by influencing the local charge environment or increasing the hydrogen-bonding capability (7–10). In addition, the PTMs optimize the interaction of ribosomes with tRNAs, mRNAs and translation factors (9,11). Therefore, any alteration of rRNA PTMs can negatively impact both translation rate and accuracy (12–14) and impair responses to metabolites and antibiotics (15). Moreover, certain PTMs are associated with altered translation in various diseases, such as cancer and infectious diseases (16–18). Therefore, the complete identification of the PTMs and their sites in human ribosomes would constitute a major advance for understanding ribosome-associated cellular physiology and pathology. Recently, using cryo-electron microscopy (cryo-EM), >130 individual rRNA modifications were visualized on the three-dimensional (3D) structure of the human 80S ribosome, and many of these PTMs were posited to be human-specific modifications (19). A large proportion of these PTMs, however, is inconsistent with those reported previously (4,5,20,21 and reference therein) in terms of both the types of chemical groups and sites of modification in human rRNA. Using a method for quantitative RNA analysis based on mass spectrometry (MS) technology termed SILNAS (stable isotope–labeled ribonucleic acid as an internal standard), we, for the first time, mapped all PTMs of the 80S ribosome from two eukaryotes, namely the fission yeast Schizosaccharomyces pombe (22) and the budding yeast Saccharomyces cerevisiae (23). Then, as a part of a cryo-EM analysis, we determined the PTMs in the Leishmania ribosome that are involved in binding the aminoglycoside paromomycin (24). We, therefore, took advantage of this technology to determine all PTMs in the entire rRNAs of the human 80S ribosome. We further investigated how human disease might alter the landscape of rRNA PTMs by assessing the PTMs of rRNAs of the 80S ribosome from patients with familial dyskeratosis congenita (DC) caused by mutations in the gene DKC1, the product of which converts uridine to Ψ. MATERIALS AND METHODS Reagents Standard laboratory chemicals were obtained from Wako Pure Chemical Industries. Sodium guanosine-13C10 5′-triphosphate (98 atom% 13C) and RNase A were obtained from Sigma-Aldrich. Sodium cytidine-13C9 5′-triphosphate and sodium uridine-13C9 5′-triphosphate (98 atom% 13C) were purchased from Santa Cruz Biotechnology. 5,6-D2-uridine was obtained from C/D/N Isotopes. RNase T1 was purchased from Worthington and further purified by reversed-phase LC before use. Triethylammonium acetate buffer (pH 7.0) was purchased from Glen Research. Chemically synthesized oligonucleotides were obtained from JBioS (the oligonucleotide sequences are given in Supplementary Table S1). Cells and culture conditions TK6 cell (human lymphoblast cell from spleen, Epstein-Barr virus transformed) and HeLa cell (human epithelial cell from cervix, adenocarcinoma) were obtained from the American Type Culture Collection. TK6 and HeLa cells were cultured at 37°C as described (25,26). Media used in this study are listed in Supplementary Table S2. To obtain U/C-5,6-D2-labeled rRNAs, TK6 cells deficient in UMPS were cultured in the U/C-5,6-D2 labeling medium containing 330 μM 5,6-D2-uridine instead of uridine with natural isotope distribution. DC fibroblasts, lymphoblastoid cell line (LCL), and control cells were obtained from Coriell Cell Repositories (GM01774, GM01786, GM01787, AG04645, GM03194, GM03195, GM03650 and AG03738, https://www.coriell.org/) or the repositories of the National Institutes of Biomedical Innovation, Health and Nutrition (KURB1983, http://cellbank.nibiohn.go.jp/). Cells were maintained in DMEM with 20% fetal bovine serum or RPMI 1640 with 2 mM l-glutamine and 15% fetal bovine serum. Information concerning the pathology associated with these cells is summarized in Supplementary Table S3. Generation of UMPS deficient TK6 cells To confirm the site of pseudouridylation, TK6 cells deficient in uridine monophosphate synthetase were generated to block de novo synthesis of uridine and grown in culture medium containing 5,6-D2-uridine (Supplementary Table S2) to differentiate the molecular mass of uridine from that of Ψ. The method used was CRISPR/Cas9 gene editing technology (27) targeting human UMPS gene (Gene ID: 7372, https://www.ncbi.nlm.nih.gov/gene/7372), and proper gene-targeting events with UMPS were confirmed by PCR using the genome DNA as a template. The details will be described elsewhere. Preparation of cellular RNA Total RNA (20 μg) was prepared from 10 ml TK6 cell culture (∼1.0 × 106 cell/ml) using Sepasol-RNA I Super G (Nacalai Tesque, Kyoto, Japan). rRNAs were purified from the total cellular RNA (∼15 μg) by reversed-phase LC on a PLRP-S 300Å column (2.1 × 100 mm, 3 μm, Agilent Technologies) or 4000 Å column (4.6 × 150 mm, 10 μm, Agilent Technologies) (28). A rRNA preparation of >95% purity was used for this study. In vitro transcription of internal standard RNAs for SILNAS To construct the plasmids for in vitro transcription of internal standard RNAs, DNAs encoding human 5S, 5.8S and 18S rRNAs were amplified by PCR from genomic DNA (PCR primers are noted in Supplementary Table S1). The amplified DNAs for 5S and 5.8S rRNAs were inserted into the EcoRI/XhoI sites of plasmid pBluescript II KS(+) (Agilent Technologies). For 18S rRNA, the amplified DNA was inserted into the KpnI/XhoI sites of plasmid pcDNA3.1(+) (Invitrogen, Carlsbad, CA, USA). For 28S rRNA, the 5′-terminal half of the PCR-amplified DNA (HindIII/BglII digest, ∼2.4 kb) and 3′-terminal half of the chemically synthesized DNA (BglII/XhoI digest, ∼2.7 kb, Wako Pure Chemical Industries) were ligated into pcDNA3.1(+) because we failed to amplify the 3′-terminal half of the DNA including the extremely GC-rich region. Before in vitro transcription, the plasmid was linearized with SpeI or XhoI to terminate the product at the end of the rRNA. To